Home > Insider Trading > Filing (0001567619-20-018012)

Filing Details

Accession Number:: 0001567619-20-018012
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-10-20 17:00:09
Reporting Period:: 2020-10-20

Accepted Time:: 2020-10-20 17:00:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1799448	Aligos Therapeutics Inc.	ALGS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619294	Thomas Woiwode	C/O Aligos Therapeutics, Inc. 1 Corporate Drive, 2Nd Floor South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-20	2,145,991	$0.00	2,145,991	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-10-20	198,839	$0.00	2,344,830	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-10-20	85,065	$0.00	2,429,895	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-10-20	463,959	$0.00	463,959	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-10-20	198,485	$0.00	662,444	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-10-20	200,000	$15.00	862,444	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-10-20	2,145,991	$0.00	2,145,991	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2020-10-20	198,839	$0.00	198,839	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2020-10-20	463,959	$0.00	463,959	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-10-20	85,065	$0.00	85,065	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-10-20	198,485	$0.00	198,485	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
These securities are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
These securities are held of record by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.